High intraocular pressure following anti-vascular endothelial growth factor therapy: Proposed pathophysiology due to altered nitric oxide metabolism

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 1, 2015, Pages 2-10

  Ricca, Aaron M ^a   Morshedi, R Grant ^a   Wirostko, Barbara M ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANTERIOR EYE CHAMBER; AQUEOUS HUMOR OUTFLOW; BLEEDING; CARDIOTOXICITY; DIGESTIVE SYSTEM PERFORATION; ENZYME INHIBITION; EYE; EYE DISEASE; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; METABOLISM; NONHUMAN; ONCOLOGY; PATHOPHYSIOLOGY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; RETINA DISEASE; REVIEW; SMOOTH MUSCLE CONTRACTILITY; SYNTHESIS; SYSTEMIC ARTERIAL HYPERTENSION; THEORY; THROMBOSIS; THYROID DISEASE; WOUND HEALING IMPAIRMENT; ANIMALS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GLAUCOMA; HUMANS; OCULAR HYPERTENSION; PHYSIOPATHOLOGY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

ANIMALS; EYE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84920800825     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0062     Document Type: Review

References (85)

1. Xu, W.M., and Liu, L.Z. Nitric oxide: From a mysterious labile factor to the molecule of the Nobel Prize. Recent progress in nitric oxide research. Cell Res. 8:251-258, 1998.
2. Beauregard, C., Brandt, P.C., and Chiou, G.C. Nitric oxide and cyclic GMP-mediated protein secretion from cultured lacrimal gland acinar cells. J. Ocul. Pharmacol. Ther. 18: 429-443, 2002.
3. Khoobehi, B., Chiroli, V., Ronchetti, D., et al. Enhanced oxygen saturation in optic nerve head of non-human primate eyes following the intravitreal injection of NCX 434, an innovative nitric oxide-donating glucocorticoid. J. Ocul. Pharmacol. Ther. 27:115-121, 2011.
4. Yanagiya, N., Akiba, J., Kado, M., et al. Transient corneal edema induced by nitric oxide synthase inhibition. Nitric Oxide. 1:397-403, 1997.
5. Carreiro, S., Anderson, S., Gukasyan, H.J., Krauss, A., and Prasanna, G. Correlation of in vitro and in vivo kinetics of nitric oxide donors in ocular tissues. J. Ocul. Pharmacol. Ther. 25:105-112, 2009.
6. Jacot, J.L., O'Neill, J.T., Scandling, D.M., West, S.D., and McKenzie, J.E. Nitric oxide modulation of retinal, choroidal, and anterior uveal blood flow in newborn piglets. J. Ocul. Pharmacol. Ther. 14:473-489, 1998.
7. Kamba, T., and McDonald, D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer. 96:1788-1795, 2007.
8. Baffert, F., Le, T., Sennino, B., et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. Heart Circ. Physiol. 290:H547-559, 2006.
9. Syrigos, K.N., Karapanagiotou, E., Boura, P., Manegold, C., and Harrington, K. Bevacizumab-induced hypertension: Pathogenesis and management. BioDrugs. 25:159-169, 2011.
10. Hoang, Q.V., Mendonca, L.S., Della Torre, K.E., et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 119:321-326, 2012.
11. Hoang, Q.V., Tsuang, A.J., Gelman, R., et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 33:179-187, 2013.
12. Good, T.J., Kimura, A.E., Mandava, N., and Kahook, M.Y. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br. J. Ophthalmol. 95: 1111-1114, 2011.
13. Mathalone, N., Arodi-Golan, A., Sar, S., et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefe's Arch. Clin. Exp. Ophthalmol. 250:1435-1440, 2012.
14. Forstermann, U., Boissel, J.P., and Kleinert, H. Expressional control of the ?constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 12:773-790, 1998.
15. Krumenacker, J.S., Hanafy, K.A., and Murad, F. Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res. Bull. 62:505-515, 2004.
16. Nathan, C.F., and Hibbs, J.B., Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3:65-70, 1991.
17. Denninger, J.W., and Marletta, M.A. Guanylate cyclase and the .NO/cGMP signaling pathway. Biochim. Biophys. Acta. 1411:334-350, 1999.
18. Sekkai, D., Aillet, F., Israel, N., and Lepoivre, M. Inhibition of NF-kappaB and HIV-1 long terminal repeat transcriptional activation by inducible nitric oxide synthase 2 activity. J. Biol. Chem. 273:3895-3900, 1998.
19. Poulos, T.L. Soluble guanylate cyclase. Curr. Opin. Struct. Biol. 16:736-743, 2006.
20. Conti, M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol. Endocrinol. 14:1317-1327, 2000.
21. Lara Lda, S., Cavalcante, F., Axelband, F., et al. Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na +-ATPase by Ang-(1-7). Biochem. J. 395:183-190, 2006.
22. Bucolo, C., and Drago, F. Carbon monoxide and the eye: Implications for glaucoma therapy. Pharmacol. Ther. 130: 191-201, 2011.
23. Mustafa, A.K., Gadalla, M.M., and Snyder, S.H. Signaling by gasotransmitters. Sci. Signal. 2:re2, 2009.
24. Altaany, Z., Yang, G., and Wang, R. Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells. J. Cell. Mol. Med. 17:879-888, 2013.
25. Meyer, P., Champion, C., Schlotzer-Schrehardt, U., Flammer, J., and Haefliger, I.O. Localization of nitric oxide synthase isoforms in porcine ocular tissues. Curr. Eye Res. 18:375-380, 1999.
26. Nathanson, J.A., and McKee, M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest. Ophthalmol. Vis. Sci. 36:1765-1773, 1995.
27. Varma, S.D., and Hegde, K.R. Susceptibility of the ocular lens to nitric oxide: Implications in cataractogenesis. J. Ocul. Pharmacol. Ther. 23:188-195, 2007.
28. Kiel, J.W. Endothelin modulation of choroidal blood flow in the rabbit. Exp. Eye Res. 71:543-550, 2000.
29. Resnikoff, S., Pascolini, D., Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82:844-851, 2004.
30. Stamer, W.D., Lei, Y., Boussommier-Calleja, A., Overby, D.R., and Ethier, C.R. eNOS, a pressure-dependent regulator of intraocular pressure. Invest. Ophthalmol. Vis. Sci. 52:9438-9444, 2011.
31. Borghi, V., Bastia, E., Guzzetta, M., et al. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J. Ocul. Pharmacol. Ther. 26:125-132, 2010.
32. Kotikoski, H., Alajuuma, P., Moilanen, E., et al. Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: Role of cyclic GMP. J. Ocul. Pharmacol. Ther. 18:11-23, 2002.
33. Schuman, J.S., Erickson, K., and Nathanson, J.A. Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys. Exp Eye Res. 58:99-105, 1994.
34. Giuffrida, S., Bucolo, C., and Drago, F. Topical application of a nitric oxide synthase inhibitor reduces intraocular pressure in rabbits with experimental glaucoma. J. Ocul. Pharmacol. Ther. 19:527-534, 2003.
35. Taniguchi, T., Kawakami, H., Sawada, A., et al. Effects of nitric oxide synthase inhibitor on intraocular pressure and ocular inflammation following laser irradiation in rabbits. Curr. Eye Res. 17:308-315, 1998.
36. Kiel, J.W., Reitsamer, H.A., Walker, J.S., and Kiel, F.W. Effects of nitric oxide synthase inhibition on ciliary blood flow, aqueous production and intraocular pressure. Exp. Eye Res. 73:355-364, 2001.
37. Krauss, A.H., Impagnatiello, F., Toris, C.B., et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp. Eye Res. 93:250-255, 2011.
38. Mincione, F., Benedini, F., Biondi, S., et al. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg. Med. Chem. Lett. 21:3216-3221, 2011.
39. Bausch + Lomb Initiates Phase 3 Program for Glaucoma Drug Candidate Licensed from Nicox. January 29, 2013. http://www.nicox.com/index.php/en/rd/ophthalmic-pipeline/latanoprostene-bunod, accessed on October 26, 2014.
40. Wiederholt M., Sturm, A., and Lepple-Wienhues, A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest. Ophthalmol. Vis. Sci. 35, 2515-2520, 1994.
41. Ellis, D.Z., Dismuke, W.M., and Chokshi, B.M. Characterization of soluble guanylate cyclase in NO-induced increases in aqueous humor outflow facility and in the trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 50:1808-1813, 2009.
42. Dismuke, W.M., and Ellis, D.Z. Activation of the BK(Ca) channel increases outflow facility and decreases trabecular meshwork cell volume. J. Ocul. Pharmacol. Ther. 25:309-314, 2009.
43. Dismuke, W.M., Mbadugha, C.C., and Ellis, D.Z. NOinduced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am. J. Physiol. Cell. Physiol. 294:C1378-C1386, 2008.
44. Ellis, D.Z., Sharif, N.A., and Dismuke, W.M. Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling. Invest. Ophthalmol. Vis. Sci. 51:5817-5824, 2010.
45. Korenbrot, J.I., and Rebrik, T.I. Tuning outer segment Ca2 + homeostasis to phototransduction in rods and cones. Adv. Exp. Med. Biol. 514:179-203, 2002.
46. Cisneros-Mejorado, A., Hernandez-Soberanis, L., Islas-Carbajal, M.C., and Sanchez, D. Capacitation and Ca(2 + ) influx in spermatozoa: Role of CNG channels and protein kinase G. Andrology. 2:145-154, 2014.
47. Nathanson, J.A., and McKee, M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest. Ophthalmol. Vis. Sci. 36:1774-1784, 1995.
48. Chang, C.J., Chiang, C.H., Chow, J.C., and Lu, D.W. Aqueous humor nitric oxide levels differ in patients with different types of glaucoma. J. Ocul. Pharmacol. Ther. 16: 399-406, 2000.
49. Kozawa, T., Sone, H., Okuda, Y., et al. Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma. Nippon Ganka Gakkai Zasshi. 102:731-738, 1998.
50. Sasamoto, Y., Oshima, Y., Miki, A., et al. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: A retrospective two-dose comparative study. J. Ocul. Pharmacol. Ther. 28: 41-48, 2012.
51. Buys, E.S., Ko, Y.C., Alt, C., et al. Soluble guanylate cyclase alpha1-deficient mice: A novel murine model for primary open angle glaucoma. PloS One. 8:e60156, 2013.
52. Josko, J., and Mazurek, M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med. Sci. Monit. 10:RA89-RA98, 2004.
53. Shibuya, M. Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 153:13-19, 2013.
54. Cavallaro, G., Filippi, L., Bagnoli, P., et al. The pathophysiology of retinopathy of prematurity: An update of previous and recent knowledge. Acta Ophthalmol. 92:2-20, 2014.
55. Shen, B.Q., Lee, D.Y., and Zioncheck, T.F. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J. Biol. Chem. 274:33057-33063, 1999.
56. Yang, R., Thomas, G.R., Bunting, S., et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol. 27:838-844, 1996.
57. Javanmard, S.H., Hasanpour, Z., Abbaspoor, Z., Naderian, G.A., and Jahanmard, M. Aqueous concentrations of VEGF and soluble VEGF receptor-1 in diabetic retinopathy patients. J. Res. Med. Sci. 17:1124-1127, 2012.
58. Bhisitkul, R.B. Vascular endothelial growth factor biology: Clinical implications for ocular treatments. Br. J. Ophthalmol. 90:1542-1547, 2006.
59. Hood, J.D.M., Meininger, C.J., Ziche, M., and Granger, H.J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 274, 1998.
60. Horowitz, J.R., Rivard, A., Van Der Zee, R., et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 17:2793-2800, 1997.
61. E G, Cao, Y., Bhattacharya, S., et al. Endogenous vascular endothelial growth factor-A (VEGF-A) maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription. J. Biol. Chem. 287:3029-3041, 2012.
62. Jakeman, L.B., Winer, J., Bennett, G.L., Altar, C.A., and Ferrara, N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. 89:244-253, 1992.
63. Fukumura, D., Gohongi, T., Kadambi, A., et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA. 98:2604-2609, 2001.
64. Robinson, E.S., Khankin, E.V., Choueiri, T.K., et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 56:1131-1136, 2010.
65. Inai, T., Mancuso, M., Hashizume, H., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165:35-52, 2004.
66. Kruzliak, P., Kovacova, G., and Pechanova, O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis. 16:289-295, 2013.
67. Dai, F., Shu, L., Bian, Y., et al. Safety of bevacizumab in treating metastatic colorectal cancer: A systematic review and meta-analysis of all randomized clinical trials. Clin. Drug Investig. 33:779-788, 2013.
68. Izzedine, H., Rixe, O., Billemont, B., Baumelou, A., and Deray, G. Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension. Am. J. Kidney Dis. 50:203-218, 2007.
69. Kahook, M.Y., and Ammar, D.A. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J. Glaucoma. 19:437-441, 2010.
70. Kernt, M., Welge-Lussen, U., Yu, A., Neubauer, A.S., and Kampik, A. Bevacizumab is not toxic to human anteriorand posterior-segment cultured cells. Ophthalmologe. 104:965-971, 2007.
71. Gismondi, M., Salati, C., Salvetat, M.L., Zeppieri, M., and Brusini, P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J. Glaucoma. 18:658-661, 2009.
72. Hollands, H., Wong, J., Bruen, R., et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can. J. Ophthalmol. 42:807-811, 2007.
73. Theoulakis, P.E., Lepidas, J., Petropoulos, I.K., et al. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin. Monbl. Augenheilkd. 227: 280-284, 2010.
74. Kim, J.E., Mantravadi, A.V., Hur, E.Y., and Covert, D.J. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am. J. Ophthalmol. 146:930-934 e931, 2008.
75. Adelman, R.A., Zheng, Q., and Mayer, H.R. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J. Ocul. Pharmacol. Ther. 26:105-110, 2010.
76. Tressler, C.S.S., Sultan, M., Huang, K., Zhou, D., and Mo, J. Effect of repeated intravitreal (IVT) injections of antivascular endothelial growth factor (VEGF) agents on intraocular pressure (IOP) in patients with age-related macular degeneration (AMD) 24th American Glaucoma Society Annual Meeting. J. Glaucoma. 2014; 164:Abstract 67.
77. Sobaci, G., Gungor, R., and Ozge, G. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: A comparative clinical study. Int. J. Ophthalmol. 6:211-215, 2013.
78. Horsley, M.B., Mandava, N., Maycotte, M.A., and Kahook, M.Y. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am. J. Ophthalmol. 150:558-561 e551, 2010.
79. Nathanson, J.A. Nitrovasodilators as a new class of ocular hypotensive agents. J. Pharmacol. Exp. Ther. 260:956-965, 1992.
80. Sniegowski, M., Mandava, N., and Kahook, M.Y. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open. Ophthalmol. J. 4:28-29, 2010.
81. Kahook, M.Y., Liu, L., Ruzycki, P., et al. High-molecularweight aggregates in repackaged bevacizumab. Retina. 30: 887-892, 2010.
82. Martinez-de-la-Casa, J.M., Ruiz-Calvo, A., Saenz-Frances, F., et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest. Ophthalmol. Vis. Sci. 53: 6214-6218, 2012.
83. Quaggin, S.E. Turning a blind eye to anti-VEGF toxicities. J. Clin. Invest. 122:3849-3851, 2012.
84. Adhi, M., Lau, M., Liang, M.C., Waheed, N.K., and Duker, J.S. Analysis of the thickness and vascular layers of the choroid in eyes with geographic atrophy using spectraldomain optical coherence tomography. Retina. 34:306-312, 2014.
85. Grunwald, J.E., Daniel, E., Huang, J., et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 121:150-161, 2014.